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Hepatitis C virus (HCV) genotypes may be investigated by a variety of laboratory methods that target
different parts of the HCV genome and have various degrees of technical difficulty. Since the choice of a
particular method is difficult, we compared the performance of (i) a type-specific PCR with type-specific
primers from the core region, (ii) molecular hybridization of the PCR-amplified 5* noncoding region to
type-specific probes, and (iii) identification of type-specific antibodies against epitopes of nonstructural region
4 by enzyme-linked immunosorbent assay (ELISA). One hundred fifty-one patients with biopsy-proved chronic
hepatitis and HCV RNA in serum were investigated. The HCV genotype was identified in 99%, 100%, and 85%
of the cases by type-specific PCR, probe hybridization, and ELISA, respectively. The type-specific PCR
disclosed infection with type 1a in 3%, type 1b in 74%, and type 3a in 4% of the cases and suggested infection
with two or more HCV types, including 2a/2c and 2b, in the remaining 18%. Apparently mixed infections were
more prevalent in patients with past intravenous drug use (P < 0.001), but cloning and sequencing of PCR
products did not confirm a mixed infection in any of the four cases investigated. Concordant results were
obtained by the three procedures with virtually all of the samples in which the type-specific PCR revealed a
single HCV genotype. Type-specific hybridization and ELISA usually recognized the genotype producing the
strongest DNA band in samples in which type-specific PCR suggested a mixed infection. In conclusion, the
three procedures evaluated in this study are reliable for investigation of HCV genotypes. Type-specific PCR
provides information about HCV subtypes, but a mixed infection detected with this method should be inter-
preted with caution.
Hepatitis C virus (HCV) is an enveloped, positive-stranded
RNA virus with marked genetic heterogeneity, as shown by
sequence analysis of isolates from different parts of the world
(2, 3). As in infections with other RNA viruses, the genetic
heterogeneity of HCV is probably related to replication errors
introduced by the RNA-dependent RNA polymerase (7, 16,
23, 36).
On the basis of comparison of nucleotide and predicted
amino acid sequences of different regions of the HCV genome,
at least six major genotypes have been described (2–4, 24, 29,
31, 35) and a new system for nomenclature was recently agreed
by several research groups (28). In this new nomenclature, the
classification of HCV into different types and subtypes is based
on sequence homology of at least two regions of the genome
and confirmed by phylogenetic tree analysis.
Recent data suggest that the natural course of the disease
(22) and the response to interferon therapy (9, 37, 39) may be
influenced by the genotype of the virus infecting each individ-
ual patient. Therefore, HCV typing may become an important
tool in clinical practice, mainly for design of therapeutic strat-
egies.
Several methods have been developed to identify HCV ge-
notypes, including PCR amplification of HCV cDNA with
type-specific primers (24), restriction fragment length poly-
morphism analysis of PCR amplicons (8, 21, 30), molecular
hybridization of type-specific probes to PCR-amplified HCV
cDNA (13, 35), genome amplification and sequencing (2, 4,
36), and identification of type-specific antibodies by enzyme-
linked immunosorbent assay (ELISA) (20, 31). Since all of
these techniques focus on different regions of the HCV ge-
nome, it may be important to explore whether genotyping by
different methods produces concordant results or not. On the
other hand, the economic cost, the degree of technical diffi-
culty, and the amount of information provided may vary con-
siderably from one procedure to another, making a choice
difficult.
We report here the results obtained with a large series of
Spanish patients with chronic hepatitis C in whom the HCV
genotype was investigated by three procedures focusing on
different regions of the HCV genome and involving distinct
methods, such as a type-specific PCR, molecular hybridization,
and ELISA for type-specific antibodies.
MATERIALS AND METHODS
Sera from 151 consecutive HCV-infected Spanish patients with biopsy-proved
chronic hepatitis referred for antiviral therapy were studied. Etiological factors
other than chronic HCV infection were ruled out in all cases. All patients had
had elevated serum aminotransferases for at least 6 months, had a positive test
for anti-HCV antibodies (third-generation ELISA [Ortho Diagnostics, Raritan,
N.J.]), and had HCV RNA in serum by reverse transcription nested PCR with
primers from the 59 noncoding region (59NCR) of the HCV genome (12, 33).
The mean age of the patients was 44 (range, 18 to 64) years. Ninety-one were
male, and 60 were female. Fifty-one patients had a history of blood transfusion,
21 had a history of intravenous drug use (IVDU), and the possible source of
infection was not determined in the remaining 79. In accordance with recently
proposed criteria (11), the histological diagnoses were mild chronic hepatitis in
60 cases, moderate chronic hepatitis in 54, and severe chronic hepatitis in 37.
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Pretherapy serum samples were obtained under appropriate conditions to
improve preservation of RNA and immediately stored at2408C until tested (10).
The HCV genotype was examined by three methods: (i) a type-specific PCR, (ii)
hybridization of type-specific probes to DNA obtained by PCR amplification of
HCV cDNA, and (iii) identification of type-specific antibodies.
HCV RNA extraction and cDNA synthesis. For detection of HCV RNA in
serum and for genotyping studies involving PCR, RNA was extracted from 180
ml of serum by the acid guanidinium isothiocyanate-phenol-chloroform method
(6), precipitated with isopropanol, and rinsed with 70% cold ethanol. The RNA
pellet was resuspended in 25 ml of diethylpyrocarbonate-treated water. cDNA
was synthesized from 7 ml of RNA with 300 U of Moloney murine leukaemia
virus reverse transcriptase (GIBCO-BRL, Gaithersburg, Md.) in the presence of
random primers and 20 U of RNase inhibitor (Promega, Madison, Wis.). The
guidelines of Kwok and Higuchi (18) were strictly observed to prevent carryover
contamination, and appropriate negative controls for RNA extraction, cDNA
synthesis, and PCRs were routinely included in each PCR round.
Type-specific PCR.Genotyping with type-specific primers from the core region
of the HCV genome was performed by type-specific PCR as described by Oka-
moto et al. (24), with the following modifications: (i) use of universal and
type-specific primers for type 3a (25), (ii) use of a modified primer for types 2a
and 2c in accordance with nucleotide sequence differences observed between
Mediterranean and Japanese HCV isolates (17, 27), and (iii) addition of 500 mM
tetramethylammonium chloride (TMAC; Sigma-Aldrich, Madrid, Spain) to the
PCR mixture to increase the specificity of annealing (15). Reactions were carried
out in a Perkin-Elmer Cetus thermal cycler with Taq DNA polymerase (GIBCO
BRL). The first round of amplification was performed with 7 ml of cDNA by
using a combination of two sense primers (256 and 256V) and one antisense
primer (186) (Table 1). The reaction consisted of 35 cycles of 958C for 1 min,
558C for 1 min, 728C for 1 min, and a final extension of 7 min. One microliter of
the PCR products was reamplified by a second PCR round (948C for 1 min, 608C
for 1 min, and 728C for 1 min for 30 cycles plus 728C for 7 min in the final cycle)
with a mixture of two sense primers (104 and 104V) and five antisense primers
(132, 133, 134m, 135, and 339) (Table 1). Type-specific PCR products were
identified by electrophoresis on 3% NuSieve and 1% SeaKem agarose (FMC
Bioproducts, Rockland, Maine) after ethidium bromide staining. A f-X174
DNA HinfI digest (Promega) was used as a molecular weight marker. Serum
samples giving more than one genotype-specific DNA band were reanalyzed, and
the presence of a mixed infection was accepted upon agreement by two inde-
pendent observers of the gels. When a type-specific PCR suggested a mixed
infection, the genotype represented by the most intense DNA band was consid-
ered the predominant genotype.
Type-specific hybridization. Genotyping by hybridization with type-specific
probes was performed as described by Gerotto et al. (13), with minor modifica-
tions. Briefly, 7 ml of cDNA was amplified with primers from the well-conserved
59NCR (12). The reaction consisted of 35 cycles of 958C for 1 min, 468C for 1
min, 728C for 1 min and a final extension for 7 min. Amplified DNA (10 ml) was
denatured with NaOH and applied to a prehumidified nylon membrane (Boehr-
inger, Mannheim, Germany) with a dot-blotting manifold and then fixed by
baking for 30 min at 1208C. Membranes were prehybridized for 60 min at 428C.
Prehybridization buffer was composed of 53 SSC (13 SSC is 0.15 M NaCl plus
0.015 M sodium citrate), 1% blocking reagent (Boehringer), 0.1% n-lauryl sar-
cosinate, and 0.02% sodium dodecyl sulfate (SDS). Hybridization was performed
by incubating the membranes overnight at 428C in the same buffer, with type-
specific 59 end digoxigenin-labelled probes synthesized from the 59NCR (30
pmol/ml). The sequences of the probes used for type-specific hybridization were
as follows: type 1, 59 CGCTCAATGCCTGGAGAT 39; type 2, 59 CACTCTAT
GCCCGGCCAT 39; type 3, 59 CGCTCAATACCCAGAAAT 39. Washing was
performed as follows: 10 min with 63 SSC–0.1% SDS at room temperature
(twice), 10 min with 33 SSC–0.1% SDS at room temperature (twice), and 15 min
with 13 SSC–0.1% SDS at 558C (twice). Thereafter, filters were incubated with
an antidigoxigenin-alkaline phosphatase conjugate and colorimetric detection
was performed with nitroblue tetrazolium salt (75 mg/ml) and 5-bromo-4-chloro-
3-indolylphosphate salt (50 mg/ml; Boehringer).
Detection of type-specific antibodies by ELISA. Type-specific antibodies to
HCV were identified by ELISA with branched oligopeptides deduced by epitope
mapping of the nonstructural region 4 (NS4) protein as described previously
(31). In this assay, plastic wells were coated with peptides (100 ng/ml) corre-
sponding to each of the three HCV types, 1, 2, and 3. Test samples at a 1:40
dilution were incubated in individual wells in the absence and in the presence of
a 100:1 molar excess of type heterologous peptides (1 plus 2, 1 plus 3, or 2 plus
3) in solution. The aim of this strategy was to ensure specificity by preventing
binding to the wells of antibodies against epitopes shared by the HCV types
present in the blocking solution. A sample was considered nonreactive when no
reaction occurred at either a 1:40 or a 1:10 dilution. A sample was considered
nontypeable when reactivity appeared with the unblocked peptides and no re-
activity appeared with the peptides in solution (31).
All of the nonreactive and nontypeable samples and the 10 typeable samples
were tested for the presence of antibodies targeting different regions of HCV;
i.e., NS4 (c100/5-1-1 peptides), NS3 (c33c antigen), core (c22 peptide), and NS5
(NS5 antigen), with a third-generation recombinant immunoblotting assay (Chi-
ron RIBA HCV 3.0; Ortho Diagnostics).
5*NCR cloning and sequencing. Cloning and sequencing analysis of the
59NCR were carried out with six samples that were selected on the basis of data
provided by a type-specific PCR. The HCV 59NCR was amplified from cDNA as
described above and cloned into a pBluescript SK(1) plasmid vector (Stratagene
Cloning Systems, La Jolla, Calif.). The DNA sequence was determined with at
least 10 clones from each patient by using the AutoRead DNA Sequencing Kit
(Pharmacia Biotech, Uppsala, Sweden) and an A.L.F. automatic DNA se-
quencer (Pharmacia Biotech). The HCV genotype present in each clone was
recognized by identification of previously described type- and subtype-specific
sequence polymorphisms of the 59NCR (8).
Statistical analysis. Differences between proportions were analyzed with the
chi square test.
RESULTS
Genotyping by type-specific PCR. The distribution of HCV
genotypes identified by the three methods compared in this
study is shown in Table 2. Type-specific DNA bands obtained
with the type-specific PCR were identified by their distinct
sizes in 149 (99%) of the 151 cases. Infection by a single type
was detected in 121 cases (80%), and extra bands, suggesting
coinfection by two or more types, were present in 28 cases
(19%), including 7 with infection by subtypes of the same
genotype.
Among the samples in which an apparent mixed infection
was identified by the type-specific PCR, we detected two types
of HCV in 15 cases, three types in 12 cases, and four types in
TABLE 1. Sequences of primers used for HCV cDNA
amplification by type-specific PCR
Designation Sequence (type)
Universal primers for 1st
PCR round
256 ..................................59 CGCGCGACTAGGAAGACTTC 39
256V...............................59 CGCGCGACGCGCAAAACTTC 39
186 ..................................59 ATGTACCCCATGAGGTCGGC 39
Universal primers for
2nd PCR round
104 ..................................59 AGGAAGACTTCCGAGCGGTC 39
104V...............................59 CGTAAAACTTCTGAACGGTC 39
Type-specific primers for
2nd PCR round
132 ..................................59 TGCCTTGGGGATAGGCTGAC 39 (1a)
133 ..................................59 GAGCCATCCTGCCCACCCCA 39 (1b)
134ma .............................59 GCCCCATGAAGGGCGAGAAC 39 (2a/2c)
135 ..................................59 ACCCTCGTTTCCGTACAGAG 39 (2b)
339 ..................................59 GCTGAGCCCAGGACCGGTCT 39 (3a)
a This primer was designed by modification of primer 134 (24) as described by
Silini et al. (27).
TABLE 2. Results of different HCV typing methods
for 151 patients with chronic hepatitis C
HCV type or
subtype
No. of samples typed by:
Type-specific
PCR
Type-specific
hybridization ELISA
1 111 124 103
1a 5
1b 106
2 5 7
2a/2c
2b
3 10 16 14
3a 10
Mixed 28 6 4
Not identified 2 23
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1 case. Genotypes 2a/2c and 2b, which were not detected in
samples with single infections, were found in 20 (71%) of 28
samples with apparently mixed infections.
Predominance of one of the coexisting types was observed in
22 of the 28 cases with apparently mixed infections; the pre-
dominant type was genotype 1a in 3 cases, genotype 1b in 4,
genotypes 2a/2c in 6, genotype 2b in 1, and genotype 3a in 8.
There were significant differences in the frequency of distribu-
tion of genotypes between patients with single and apparently
mixed infections. Genotype 1b was detected in 88% of patients
with single infections but it was the predominant type in only
14% of those with apparently mixed infections (P , 0.001). In
contrast, genotypes 2 and 3 were rare or absent in samples in
which a single genotype was identified but very common in
those with apparently mixed genotypes. The epidemiological
features of patients with single infections and those with ap-
parently mixed infections were significatively different, since a
history of IVDU was rare in the former (5.8%) but common in
the latter (50%) (P , 0.001).
Genotyping by type-specific hybridization. All of the sera
could be typed by type-specific hybridization. Infection with a
single genotype was detected in 145 (96%) of 151 patients, and
mixed infections were observed in only 6 patients (4%) (Table
2).
Genotyping by ELISA. The infecting genotype was identified
by ELISA in 128 samples (85%). Single infections were found
in 124 cases (82%), and mixed infections were found in 4
(2.6%). The HCV genotype was not identified by ELISA in 23
samples, of which 13 were reactive but nontypeable and 10
were nonreactive. Among these 23 samples, the type-specific
PCR showed type 1b in 18 cases, type 3a in 1, and mixed
infections in 4. Thus, the distributions of HCV genotypes (as
identified by the type-specific PCR) in samples with typeable
and nontypeable infections by ELISA were similar.
The 13 reactive but nontypeable, 5 of the 10 nonreactive,
and the 10 typeable samples studied showed strong reactivity
against all of the Chiron RIBA HCV 3.0 peptides, including
those from NS4. The remaining five nonreactive samples were
strongly reactive for c33c and c22p but did not react against
NS4 or NS5 peptides.
Comparison of methods. HCV genotype identification was
achieved in 99% of the cases by type-specific PCR, in 100% by
type-specific hybridization, and in 85% by ELISA. The results
provided in each individual case by the three methods were
remarkably concordant when only the predominant genotype
detected by type-specific PCR was considered.
Among the 121 samples in which a type-specific PCR dis-
closed infection by a single HCV genotype, type-specific hy-
bridization gave concordant results in more than 95% of the
cases (Table 3). Remarkably concordant results were also ob-
tained by ELISA, although this technique gave no information
on 18 of these 121 patients. A major disagreement between the
results obtained by ELISA and the other two procedures oc-
curred for only one patient, in whom the ELISA recognized
HCV type 1 whereas the type-specific PCR and type-specific
hybridization recognized type 3.
Type-specific hybridization identified a single genotype in 18
of the 21 samples in which the type-specific PCR suggested
mixed infections with different major genotypes. In these cases,
type-specific hybridization identified the genotype that ap-
peared predominant in the type-specific PCR analysis. In the
seven samples in which the type-specific PCR disclosed two
subtypes of the same genotype (1a plus 1b or 2a/2c plus 2b),
the common type (1 or 2) was identified by type-specific hy-
bridization. A partial discrepancy between the results obtained
by the type-specific PCR (2a/2c plus 2b) and type-specific hy-
bridization (2 plus 1) occurred in only one case (Table 4).
Genotyping by ELISA and by type-specific PCR produced
remarkably concordant results with samples in which the type-
specific PCR disclosed apparently mixed infections. Among
the 22 samples in which the type-specific PCR suggested the
predominance of one genotype, ELISA identified the predom-
inant genotype in 18 cases. In two samples with which the
type-specific PCR produced more than one DNA band, ELISA
identified two concordant genotypes. No major disagreement
among the ELISA, the type-specific PCR, and type-specific
hybridization was observed in any case (Table 4).
Cloning and sequencing of the 5*NCR. Two samples with a
single infection (type 3a) and four samples with apparently
mixed infections (1a plus 1b in two cases, 1b plus 3a in one, and
TABLE 3. Distribution of HCV types among 121 patients infected
by a single HCV type as assessed by type-specific PCR and
relationship with results obtained by type-specific
hybridization and by ELISA
HCV type deter-
mined by type-
specific PCR
Total no. of
samples
HCV type(s) (no. of samples)
determined by:
Type-specific
hybridization ELISA
1a 5 1 (5) 1 (5)
1b 106 1 (105) 1 (87)
1b 1 1 2 (1) 1 1 2 (2)
1b NRa or NTSb (17)
3a 10 3 (9) 3 (8)
3a 3 1 1 (1) 1 (1)
3a NTS (1)
a NR, nonreactive sera.
b NTS, non-type-specific antibodies detected.
TABLE 4. HCV types in 28 patients with mixed infections
identified by type-specific PCR and relationship with results
of typing by type-specific hybridization and ELISAa
HCV type(s)
determined by
type-specific PCR
Total no. of
samples
HCV type(s) (no. of samples)
identified by:
Type-specific
hybridization ELISA
1b 1 1a 2 1 (2) 1 (1)
NRb (1)
1b 1 2a/2c 1 1 (1) 1 1 2 (1)
1b 1 2b 1 1 (1) 1 (1)
2a/2c 1 1b 1 2 (1) 2 (1)
2a/2c 1 2b 1 21 1 (1) 2 (1)
3a 1 1b 2 31 1 (1) NTSc (2)
3a 1 1b 3 (1)
3a 1 2b 1 3 (1) 3 (1)
1a 1 1b 1 2b 3 1 (3) 1 (3)
2a/2c 1 1b 1 2b 4 2 (2) 2 (3)
2a/2c 1 1b 1 2b 2 1 1 (2) 2 1 1 (1)
2b 1 1a 1 1b 1 2 (1) 2 (1)
3a 1 1b 1 1a 1 3 (1) NR (1)
3a 1 1b 1 2b 3 3 (3) 3 (3)
3a 1 1a 1 1b 1 2b 1 3 (1) 3 (1)
1a 1 1b 3 1 (3) 1 (3)
1b 1 2b 2 1 (2) 1 (1)
1b 1 2b NTS (1)
2a/2c 1 2b 1 2 (1) 2 (1)
a Bold characters identify the predominant genotype in type-specific PCR
experiments.
b NR, nonreactive sera.
c NTS, non-type-specific antibodies detected.
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1a plus 1b plus 3a in another) according to the type-specific
PCR were studied. A single HCV type was identified in 10 to
13 clones sequenced from each patient. In the two cases in
which the type-specific PCR suggested a 1a-plus-1b coinfec-
tion, 10 type 1a sequences were identified in one case and 10
type 1b sequences were identified in the other. Only type 3a
sequences were identified in the clones analyzed from the two
samples with apparently mixed infections with type 3a and
other genotypes and from the two samples with a type 3a single
infection.
The genotype identified by cloning and sequencing always
agreed with the genotype that produced the most intense DNA
band in type-specific PCR experiments.
DISCUSSION
Identification of the infecting virus genotype has become
relevant in the investigation of many aspects of HCV infection,
including epidemiology, pathogenesis, and response to antivi-
ral therapy. Several laboratory procedures aimed at identifying
the HCV genotype have been described. A PCR with type-
specific primers from the core region, as described by Oka-
moto et al. (24, 25), has been extensively used. Other assays
based on type-specific PCR amplification with type-specific
primers from other regions of the HCV genome, such as NS5,
have also been described (5). Inno-LiPA is also a widely used
assay that is based on the hybridization of amplified cDNA
from the 59NCR to specific oligonucleotide probes immobi-
lized on a membrane strip (34). HCV can also be typed by
restriction fragment length polymorphism analysis of ampli-
cons from different regions of the viral genome (21), including
the 59NCR (8, 30). Identification of major HCV types can also
be carried out by hybridization of amplicons from the 59NCR
to radiolabelled probes specific for genotypes 1, 2, and 3 (13).
All of these procedures are technically complex, time-con-
suming, and expensive and therefore not readily applicable to
routine use. In addition, PCR-based HCV genotyping cannot
be performed in cases with very low levels of viremia or if HCV
RNA has been degraded by inadequate handling of samples.
To overcome these inconveniences, efforts have been made to
identify antibodies against type-specific HCV epitopes by sim-
ple serological techniques. Machida et al., by using peptides
derived from the core region, were able to distinguish type 1
and 2 HCV infections, but this technique did not provide
information in a relatively high proportion of the subjects (20).
More recently, Simmonds et al. were able to identify HCV
types 1, 2, and 3 in up to 90% of the patients examined with an
ELISA using NS4 peptides derived from identified type-spe-
cific immunodominant epitopes (31).
Since the laboratory procedures for HCV typing are very
heterogeneous, a comparative analysis of the specificity and
sensitivity of these methods may provide useful information.
To this purpose, the HCV genotype was investigated by three
methods in a relatively large series of patients with chronic
HCV infection.
In the current study, the type-specific PCR and type-specific
hybridization were very sensitive. ELISA, which was able to
identify the infecting genotype in 85% of the cases, was some-
what less sensitive. Interestingly, type-specific hybridization
achieved high sensitivity despite the use of digoxigenin-labelled
probes instead of the radiolabelled probes originally described
(13).
Why some sera cannot be genotyped by ELISA is poorly
understood. In this study, antibodies against NS4 and NS5
peptides were not detected by the Chiron RIBAHCV 3.0 assay
in 5 of the 10 samples that were nonreactive in the ELISA,
suggesting that humoral response against some antigenic re-
gions of HCV may be weak or absent in some patients. In
contrast, ELISA-reactive but nontypeable sera showed strong
reactivity against the peptides present in Chiron RIBA HCV
3.0 strips. The reasons why HCV cannot be specifically typed
by ELISA in reactive sera are unknown.
Another key point is to ascertain whether data from differ-
ent genotyping methods are comparable or not. The three
procedures evaluated in this study showed concordant geno-
typing results in almost all of the cases in which the type-
specific PCR detected a single genotype. In those cases in
which the type-specific PCR suggested infection by two or
more genotypes, the ELISA and probe-specific hybridization
detected the genotype that produced the most intense band in
type-specific PCRs. Results concordant among the three meth-
ods were observed irrespectively of the genotype involved in
each case.
As in this study, concordance between different genotyping
methods that focus on different regions of the HCV genome
has been reported by others (19). These observations suggest
that the sequence heterogeneity defining each genotype is
maintained along different regions of the HCV genome (8, 32).
Analysis of epidemiological data showed marked differences
between patients with single infections and those with appar-
ently mixed infections suggested by type-specific PCR. A his-
tory of IVDU was rare in the former, whereas it was present in
one-half of the latter. Repeated exposure to HCV may favor
infection by different HCV strains. Furthermore, the marked
differences in genotype distribution between patients with sin-
gle and apparently mixed infections suggested by the type-
specific PCR may reasonably be attributed to differences be-
tween the patterns of exposure to infection of patients from
these two groups.
However, a unique HCV type was detected by ELISA or by
type-specific hybridization in the majority of the samples in
which mixed genotypes were detected by the type-specific
PCR. A possible explanation may be the generation of addi-
tional DNA bands by the type-specific PCR. Nonspecific an-
nealing of primers might produce amplicons of different sizes
despite the presence of a single HCV cDNA template. In fact,
it has been reported that the primer specific for type 1b may
react with type 1a, giving rise to false-positive 1a-plus-1b mixed
amplifications (1). Such falsely positive reactions have been
frequently observed in patients from Canada, where infection
with type 1a is highly prevalent (1), and also in European
patients (14, 17). Giannini et al. observed that some 1a-plus-1b
and 1b-plus-3a apparently mixed infections detected by type-
specific PCR in European patients were disclosed as 1a, 1b, or
3a single infections by LiPA typing (14).
On the other hand, several reasons might support the idea
that nonspecific annealing of a type 1b primer to type 1a cDNA
does not explain why a relatively large proportion of patients in
this study appeared to harbor a 1a-plus-1b mixed infection.
First, type 1a HCV infection is relatively uncommon in Med-
iterranean countries (22, 26). Second, a type-specific PCR was
carried out with a mixture of the five type-specific primers,
which creates competition between PCR reagents and favors
the specificity of the reaction (24). Finally, addition of TMAC
to PCR mixtures seems to enhance annealing specificity. When
cDNAs from three patients infected with type 1a alone were
studied by an identical type-specific PCR procedure without
addition of TMAC to the amplification mixture, bands of 57
and 144 bp, corresponding to genotypes 1a and 1b, were con-
sistently obtained (data not shown). In oligonucleotide hybrid-
ization experiments, it has been shown that addition of TMAC
abolishes the preferential melting of AT˙ versus CG˙ base pairs
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and makes stringency dependent on the length of the probe
(38). In PCRs, addition of TMAC at a low concentration dra-
matically reduces nonspecific priming events and increases the
specificity of the reaction with no inhibitory effect on TaqDNA
polymerase activity (15).
There are several alternatives to explain the relatively high
rate of mixed infection detected by the type-specific PCR. The
presence in a given sample of HCV genotypes other than 1a or
1b or those genotypes not detectable by type-specific PCR
(such as 1c, 3b, 3c, 4a, 5a, or 6a, occasionally present in Eu-
rope), can produce nonspecific priming and weak extra DNA
bands. Another explanation may be that sequence heteroge-
neity of the core region present in European type 2 isolates can
lead to mistyping by type-specific PCR (14, 17). This possibility
is supported by the current study, in which type 2 was always
detected as part of apparently mixed infections despite the use
of a modified primer to detect Mediterranean type 2a and 2c
isolates. Finally, the observation that type 3a was detected as
part of apparently mixed infections in 8 of 18 cases suggests
that the variability of the core region might also produce non-
specific bands when samples containing type 3a are analyzed by
type-specific PCR.
The possible lack of specificity of the type-specific PCR in
HCV genotyping studies can only be ruled out with certainty by
sequence analysis of an appropriate number of clones derived
from the amplified PCR product. In four cases with apparently
mixed infections, as suggested by type-specific PCRs, a unique
HCV type was identified by 59NCR sequence analysis of at
least 10 clones from each patient. These observations suggest
that nonspecific priming is not completely prevented by addi-
tion of TMAC to the type-specific PCR mixture. Patients with
past IVDU are more likely to be infected with genotypes other
than 1 (22), and this may favor overestimation of mixed infec-
tion by a type-specific PCR. Therefore, the epidemiological
association of mixed infection with a history of IVDU observed
in this study might be an artifact.
Theoretically, in true mixed infections, one of the genotypes
might be represented in an extremely large proportion with
respect to the others. Therefore, nonpredominant types pres-
ent in a mixed viral population could be underestimated by
analysis of only 10 clones. However, nonpredominant types
might be detected by the type-specific PCR, which is extremely
sensitive. Investigation of a very large number of clones may be
required to confirm whether a mixed infection detected by the
type-specific PCR is true or not.
In summary, the highly concordant genotyping results of this
study suggest that the three laboratory techniques evaluated
may reliably be used in genotyping studies of HCV. Each
procedure has advantages and drawbacks. ELISA is rapid and
simple and, in contrast with other genotyping methods, does
not require the strict conditions necessary for HCV RNA pres-
ervation in serum samples. However, ELISA is somewhat less
sensitive and does not allow identification of HCV subtypes.
Probe-specific hybridization, which is more complex and time-
consuming, offers greater sensitivity for identification of major
genotypes. The type-specific PCR, as used in this study, is also
complex and demands great care for specificity but provides
virus subtype information, in contrast to the other procedures.
Detection of a mixed infection by a type-specific PCR is rela-
tively frequent and should be interpreted with caution.
ACKNOWLEDGMENTS
This work was supported in part by grant 94/848 from the Fondo de
Investigaciones Sanitarias, Ministerio de Sanidad. X. Forns is the re-
cipient of an Emilio Letang grant from the Hospital Clı´nic i Provincial,
Barcelona, Spain. F. X. Lo´pez-Labrador is supported by the Spanish
Ministerio de Educacio´n y Ciencia (grant FPI-AP91/43508114). S.
Ampurdane´s and E. Olmedo are supported by the Fundacio´ Catalana
per L’Estudi de les Malalties del Fetge.
REFERENCES
1. Andonov, A., and R. K. Chaudhary. 1994. Genotyping of Canadian hepatitis
C virus isolates by PCR. J. Clin. Microbiol. 32:2031–2034.
2. Bukh, J., R. H. Purcell, and R. H. Miller. 1993. At least 12 genotypes of
hepatitis C virus predicted by sequence analysis of the putative E1 gene of
isolates collected worldwide. Proc. Natl. Acad. Sci. USA 90:8234–8238.
3. Cha, T. A., E. Beall, B. Irvine, J. Kolberg, D. Chien, G. Quo, and M. S.
Urdea. 1992. At least five related, but distinct, hepatitis C viral genotypes
exist. Proc. Natl. Acad. Sci. USA 89:7144–7188.
4. Chan, S. W., F. McOmish, E. C. Holmes, B. Dow, J. F. Peutherer, E. Follett,
P. L. Yap, and P. Simmonds. 1992. Analysis of a new hepatitis C virus type
and its phylogenetic relationship to existing variants. J. Gen. Virol. 73:1131–
1141.
5. Chayama, K., A. Tsubota, Y. Arase, S. Saitoh, I. Koida, K. Ikeda, T. Mat-
sumoto, M. Kobayashi, S. Iwasaki, S. Koyama, T. Morinaga, and H. Ku-
mada. 1993. Genotypic subtyping of hepatitis C virus. J. Gastroenterol.
Hepatol. 8:150–156.
6. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation
by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Bio-
chem. 162:156–159.
7. Choo, Q. L., K. H. Richman, J. H. Han, K. Berger, C. Lee, C. Dong, C.
Gallagos, D. Coit, R. Medina-Selby, P. J. Barr, A. J. Weiner, D. W. Bradley,
G. Kuo, and M. Houghton. 1991. Genetic organization and diversity of the
hepatitis C virus. Proc. Natl. Acad. Sci. USA 88:2451–2455.
8. Davidson, F., P. Simmonds, J. C. Ferguson, L. M. Jarvis, B. C. Dow, E. A. C.
Follett, A. J. Keller, T. Kruisius, C. Lin, G. A. Medgyesu, H. Kiyokawa, G.
Olim, G. Duraisamy, T. Cuypers, A. A. Seed, D. Teo, J. Conradie, M. C. Kew,
M. Lin, C. Nuchaprayoon, O. K. Ndimbe, and P. L. Yap. 1995. Survey of
major genotypes and subtypes of hepatitis C virus using RFLP of sequences
amplified from the 59 non-coding region. J. Gen. Virol. 76:1197–1204.
9. Davis, G. L. 1994. Prediction of response to interferon treatment of chronic
hepatitis C. J. Hepatol. 21:1–3.
10. Davis, G. L., J. Y. Lau, M. S. Urdea, P. D. Neuwald, J. C. Wilber, K. Lindsay,
R. P. Perrillo, and J. Albrecht. 1994. Quantitative detection of hepatitis C
virus (HCV) RNA by a solid-phase signal amplification method: definition of
optimal conditions for specimen collection and clinical application in inter-
feron treated patients. Hepatology 19:1337–1341.
11. Desmet, V. J., M. Gerber, J. H. Hoofnagle, M. Manns, and P. J. Scheuer.
1994. Classification of chronic hepatitis: diagnosis, grading, and staging.
Hepatology 19:1515–1520.
12. Garson, J. A., C. Ring, P. Tuke, and R. S. Tedder. 1990. Enhanced detection
by PCR of hepatitis C virus RNA. Lancet 336:878–879. (Letter.)
13. Gerotto, M., P. Pontisso, F. Giostra, S. Francesconi, L. Muratori, G. Bal-
lardini, M. Lenci, S. Timinetzky, F. B. Bianchi, F. B. Baralle, and A. Alberti.
1994. Analysis of the hepatitis C genome in patients with anti-LKM-1 auto-
antibodies. J. Hepatol. 21:273–276.
14. Giannini, C., V. Thiers, J. B. Nousbaum, L. Stuyver, G. Maertens, and C.
Brechot. 1995. Comparative analysis of two assays for genotyping hepatitis C
virus based on genotype-specific primers or probes. J. Hepatol. 23:246–253.
15. Hung, T., K. Mak, and K. Fong. 1990. A specificity enhancer for polymerase
chain reaction. Nucleic Acids Res. 18:4953.
16. Kato, N., M. Hijikata, Y. Oostuyama, M. Nakagawa, S. Ohkoshi, T. Su-
jimura, and K. Shimotohno. 1990. Molecular cloning of the human hepatitis
C virus genome from Japanese patients with non-A, non-B hepatitis. Proc.
Natl. Acad. Sci. USA 87:9524–9528.
17. Kleter, G. E. M., L. J. Van Doorn, L. Stuyver, G. Maertens, J. T. Brouwer,
S. W. Schalm, R. A. Heijtink, and W. G. V. Quint. 1995. Rapid genotyping of
hepatitis C virus RNA isolates obtained from patients residing in Western
Europe. J. Med. Virol. 47:35–42.
18. Kwok, S., and R. Higuchi. 1989. Avoiding false positives with PCR. Nature
(London) 339:237–238.
19. Lau, J. Y. N., M. Mizokami, J. A. Kolberg, G. L. Davis, L. E. Prescott, T.
Ohno, R. P. Perrillo, K. L. Lindsay, R. G. Gish, M. Kohara, P. Simmonds,
and M. Urdea. 1995. Application of six hepatitis C virus genotyping systems
to sera from chronic hepatitis C patients in the United States. J. Infect. Dis.
171:281–289.
20. Machida, A., H. Ohnuma, F. Tsuda, E. Munekata, T. Tanaka, Y. Akahane,
H. Okamoto, and S. Mishiro. 1992. Two distinct subtypes of hepatitis C virus
defined by antibodies directed to the putative core protein. Hepatology
16:886–891.
21. Nakao, T., N. Enomoto, N. Takada, A. Takada, and T. Date. 1991. Typing of
hepatitis C virus genomes by restriction fragment length polymorphism.
J. Gen. Virol. 72:2105–2112.
22. Nousbaum, J. P., S. Pol, B. Nalpas, P. Landais, P. Berthelot, C. Brechot, and
the Collaborative Study Group. 1995. Hepatitis c virus type 1b (II) infection
in France and Italy. Ann. Intern. Med. 122:161–168.
23. Okamoto, H., M. Kojima, S. I. Okada, H. Yoshizawa, H. Iizuka, T. Tanaka,
E. E. Muchmore, D. A. Peterson, Y. Ito, and S. Mishiro. 1992. Genetic drift
2520 FORNS ET AL. J. CLIN. MICROBIOL.
of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability
and stability. Virology 190:894–899.
24. Okamoto, H., Y. Sugiyama, S. Okada, K. Kurai, Y. Akahane, Y. Sugai, T.
Tanaka, K. Sato, F. Tsuda, Y. Miyakawa, and M. Marumi. 1992. Typing
hepatitis C virus by polymerase chain reaction with type-specific primers:
application to clinical surveys and tracing infectious sources. J. Gen. Virol.
73:673–679.
25. Okamoto, H., H. Tokita, M. Sakamoto, M. Horikita, M. Kojima, H. Iizuka,
and S. Mishiro. 1993. Characterization of the genomic sequence of type V
(or 3a) hepatitis C virus isolates and PCR primers for specific detection.
J. Gen. Virol. 74:2385–2390.
26. Pernas, M., J. Bartolome´, I. Castillo, J. A. Quiroga, M. Pardo, and V.
Carren˜o. 1995. Sequence of non-structural regions 3 and 5 of hepatitis C
virus genomes from Spanish patients: existence of a predominant variant
related to type 1b. J. Gen. Virol. 76:415–420.
27. Silini, E., F. Bono, A. Cerino, V. Piazza, E. Solfia, and M. U. Mondelli. 1993.
Virological features of hepatitis C virus infection in hemodialysis patients.
J. Clin. Microbiol. 31:2913–2917.
28. Simmonds, P., A. Alberti, H. J. Alter, F. Bonino, D. W. Bradley, C. Brechot,
J. T. Brouwer, S. W. Chan, K. Chayama, D. S. Chen, Q. L. Choo, M.
Colombo, H. T. M. Cuypers, T. Date, G. M. Dusheiko, J. I. Esteban, O. Fay,
S. J. Hadziyannis, J. Han, A. Hatzakis, E. C. Holmes, H. Otta, M. Houghton,
B. Irvine, M. Kohara, J. A. Kolberg, G. Kuo, J. Y. N. Lau, P. N. Lelie, G.
Maertens, F. McOmish, T. Miyamura, M. Mizokami, A. Nomoto, A. M.
Prince, H. W. Reesink, C. Rice, M. Roggendorf, S. W. Schalm, T. Shikata, K.
Shimotohno, L. Stuyver, C. Trepo, A. Weiner, P. L. Yap, and M. S. Urdea.
1994. A proposed system for the nomenclature of hepatitis C viral genotypes.
Hepatology 19:1321–1324.
29. Simmonds, P., E. C. Holmes, T. A. Cha, S. W. Chan, F. McOmish, B. Irvine,
E. Beall, P. L. Yap, J. Kolberg, and M. S. Urdea. 1993. Classification of
hepatitis C virus into six major genotypes and a series of subtypes by phy-
logenetic analysis of the NS-5 region. J. Gen. Virol. 74:2391–2399.
30. Simmonds, P., F. McOmish, P. L. Yap, S. W. Chan, C. K. Lin, G. Dusheiko,
A. A. Saeed, and E. C. Holmes. 1993. Sequence variability in the 59 non-
coding region of hepatitis C virus: identification of a new virus type and
restrictions on sequence diversity. J. Gen. Virol. 74:661–668.
31. Simmonds, P., K. A. Rose, S. Graham, S.-W. Chan, F. McOmish, B. C. Dow,
E. A. C. Follett, P. L. Yap, and H. Marsden. 1993. Mapping of serotype-
specific, immunodominant epitopes in the NS-4 region of hepatitis C virus
(HCV): use of type-specific peptides to serologically differentiate infections
with HCV types 1, 2, and 3. J. Clin. Microbiol. 31:1493–1503.
32. Simmonds, P., D. B. Smith, F. McOmish, P. L. Yap, J. Kolberg, M. S. Urdea,
and E. C. Holmes. 1994. Identification of genotypes of hepatitis C virus by
sequence comparisons in the core, E1 and NS-5 regions. J. Gen. Virol.
75:1053–1061.
33. Simmonds, P., L. Q. Zhang, H. G. Watson, S. Rebus, E. D. Ferguson, P.
Balfe, G. H. Leadbetter, P. L. Yap, J. F. Peutherer, and C. A. Ludlam. 1990.
Hepatitis C quantification and sequencing in blood products, haemophiliacs,
and drug users. Lancet 336:1469–1472.
34. Stuyver, L., R. Rossau, A. Wyseur, M. Duhamel, B. Vanderborght, H. Van
Heuverswyn, and G. Maertens. 1993. Typing of hepatitis C virus isolates and
characterization of new subtypes using a line probe assay. J. Gen. Virol.
74:1093–1102.
35. Takada, N., S. Takase, N. Enomoto, A. Takada, and T. Date. 1992. Clinical
backgrounds of the patients having different types of hepatitis C virus ge-
nomes. J. Hepatol. 14:35–40.
36. Tanaka, T., N. Kato, M. Nakagawa, Y. Ootsuyama, M. J. Cho, T. Nakazawa,
and M. Hijikata. 1992. Molecular cloning of hepatitis C virus genome from
a single Japanese carrier: sequence variation within the same individual and
among infected individuals. Virus Res. 23:39–53.
37. Tsubota, A., K. Chayama, K. Ikeda, A. Yasuji, I. Koida, S. Saitoh, M.
Hashimoto, S. Iwasaki, M. Kobayashi, and K. Hiromitsu. 1994. Factors
predictive of response to interferon-alpha therapy in hepatitis C virus infec-
tion. Hepatology 19:1088–1094.
38. Wood, W. I., J. Gitschier, L. A. Lasky, and R. M. Lawn. 1985. Base compo-
sition-independent hybridization in tetramethyl-ammonium chloride: a
method for oligonucleotide screening of highly complex gene libraries. Proc.
Natl. Acad. Sci. USA 82:1585–1588.
39. Yoshioka, K., S. Kakumu, T. Wakita, T. Ishikawa, Y. Itoh, M. Takayanagi,
Y. Higashi, M. Shibata, and T. Morishima. 1992. Detection of hepatitis C
virus by polymerase chain reaction and response to interferon-alpha therapy:
relationship to genotypes of hepatitis C virus. Hepatology 16:293–299.
VOL. 34, 1996 HCV TYPING IN SPANISH PATIENTS 2521
